PMID- 25683938
OWN - NLM
STAT- MEDLINE
DCOM- 20150811
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 2
DP  - 2015
TI  - Sorafenib combined with percutaneous radiofrequency ablation for the treatment of 
      medium-sized hepatocellular carcinoma.
PG  - 247-55
LID - 8409 [pii]
AB  - OBJECTIVE: Sorafenib, an oral multikinase inhibitor, is the proved therapy method 
      for patients with advanced hepatocellular carcinoma (HCC). Based on heat 
      delivery, Radiofrequency ablation (RFA) has been found to achieve complete 
      neoplasm necrosis. It is the most widely performed percutaneous therapy for HCC. 
      However, Study associated combined Sorafenib with RFA therapy for patients with 
      advanced HCC has never been reported. The aim of present study is to explore the 
      efficacy and safety of sorafenib combined with RFA therapy for the patients with 
      medium-sized HCC. PATIENTS AND METHODS: A total of 62 patients diagnosed as HCC 
      were involved in this study. All patients were randomly assigned to sorafenib and 
      RFA (n=30) or RFA-alone (n=32) treatment groups. Treatment outcomes, including 
      recurrence rates, time to progression (TTP) and adverse reactions induced by 
      sorafenib were observed and recorded to assess the efficacy and safety of the 
      combination method. RESULTS: During the overall follow-up period, the recurrence 
      rate of the combination subgroup was 56.7% (17/30), and that of the RFA-alone 
      subgroup was 87.5% (28/32) (p < 0.01). The median TTP was 17.0 months in the 
      combination therapy vs. 6.1 months in the RFA-alone (p < 0.05). Hand-foot skin 
      reactions were reported by 83.3% (25/30) of patients and 46.7% (14/30) reported 
      diarrhea while the most adverse events (AEs) were mild to moderate in the 
      combination subgroup. CONCLUSIONS: Sorafenib combined with RFA significantly 
      decreased recurrence rates and prolonged the survival time of medium-sized HCC 
      patients. The combination therapy is safer and more effective than the control 
      without unexpected side effects. Furthermore, the earlier application, the better 
      results were.
FAU - Kan, X
AU  - Kan X
AD  - Department of Interventional Therapy Center, Ji'nan Infectious Disease Hospital, 
      Ji'nan, China. kuihualicn@126.com.
FAU - Jing, Y
AU  - Jing Y
FAU - Wan, Q-Y
AU  - Wan QY
FAU - Pan, J-C
AU  - Pan JC
FAU - Han, M
AU  - Han M
FAU - Yang, Y
AU  - Yang Y
FAU - Zhu, M
AU  - Zhu M
FAU - Wang, Q
AU  - Wang Q
FAU - Liu, K-H
AU  - Liu KH
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
CIN - Eur Rev Med Pharmacol Sci. 2015;19(14):2521-2. PMID: 26221876
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy/pathology/*therapy
MH  - Catheter Ablation/*methods
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Liver Neoplasms/drug therapy/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Sorafenib
MH  - Treatment Outcome
EDAT- 2015/02/17 06:00
MHDA- 2015/08/12 06:00
CRDT- 2015/02/17 06:00
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/08/12 06:00 [medline]
AID - 8409 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015;19(2):247-55.